

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 October 2022 (13.10.2022)



(10) International Publication Number
WO 2022/216915 A1

(51) International Patent Classification:
C12N 15/86 (2006.01)

(21) International Application Number:
PCT/US2022/023807

(22) International Filing Date:
07 April 2022 (07.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/172,518 08 April 2021 (08.04.2021) US
63/299,254 13 January 2022 (13.01.2022) US

(71) Applicant: SANA BIOTECHNOLOGY, INC. [US/US];
188 East Blaine Street, Suite 400, Seattle, Washington
98102 (US).

(72) Inventors; and

(71) Applicants: CRUITE, Patricia [US/US]; c/o Sana
Biotechnology, Inc., 188 East Blaine Street, Suite 400,
Seattle, Washington 98102 (US). AMATYA, Shirisha
[US/US]; c/o Sana Biotechnology, Inc., 188 East Blaine
Street, Suite 400, Seattle, Washington 98102 (US).
HARDING, Hugh [US/US]; c/o Sana Biotechnology, Inc.,
188 East Blaine Street, Suite 400, Seattle, Washington

98102 (US). MACKENZIE, Lauren [US/US]; c/o Sana
Biotechnology, Inc., 188 East Blaine Street, Suite 400, Seat-
tle, Washington 98102 (US).

(74) Agent: ROBERTS, Jessica L. et al.; Finnegan, Henderson,
Farabow, Garrett & Dunner, LLP, 901 New York Avenue,
NW, Washington, District of Columbia 20001 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: CD8-SPECIFIC ANTIBODY CONSTRUCTS AND COMPOSITIONS THEREOF





FIG. 11A



(57) Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD8. Also disclosed are fusion proteins comprising a Henipavirus glycoprotein G and CD8 antibodies for targeting and transducing cells expressing CD8. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

[Continued on next page]

WO 2022/216915 A1

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*